Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has announced the cessation of 30,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting the challenges in meeting certain operational conditions.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company specializes in regenerative medicine, aiming to address significant unmet medical needs across various therapeutic areas.
YTD Price Performance: -31.82%
Average Trading Volume: 417,938
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.26B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue